KR20020048941A - 유착 형성을 억제하기 위한 방법 및 조성물 - Google Patents

유착 형성을 억제하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20020048941A
KR20020048941A KR1020027003796A KR20027003796A KR20020048941A KR 20020048941 A KR20020048941 A KR 20020048941A KR 1020027003796 A KR1020027003796 A KR 1020027003796A KR 20027003796 A KR20027003796 A KR 20027003796A KR 20020048941 A KR20020048941 A KR 20020048941A
Authority
KR
South Korea
Prior art keywords
antagonist molecule
monoclonal antibody
composition
extracellular matrix
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027003796A
Other languages
English (en)
Korean (ko)
Inventor
체레쉬데이비드에이
레씨브루스
Original Assignee
빙검 더글라스 에이.
더 스크립스 리서치 인스티튜트
프란시스 제이 메이어
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 빙검 더글라스 에이., 더 스크립스 리서치 인스티튜트, 프란시스 제이 메이어, 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 filed Critical 빙검 더글라스 에이.
Publication of KR20020048941A publication Critical patent/KR20020048941A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020027003796A 1999-09-23 2000-09-22 유착 형성을 억제하기 위한 방법 및 조성물 Ceased KR20020048941A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
US09/405,522 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
KR20020048941A true KR20020048941A (ko) 2002-06-24

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027003796A Ceased KR20020048941A (ko) 1999-09-23 2000-09-22 유착 형성을 억제하기 위한 방법 및 조성물

Country Status (9)

Country Link
EP (1) EP1223962A4 (https=)
JP (1) JP2003509468A (https=)
KR (1) KR20020048941A (https=)
CN (1) CN1399554A (https=)
AU (1) AU781442B2 (https=)
BR (1) BR0014222A (https=)
CA (1) CA2384812A1 (https=)
MX (1) MXPA02003079A (https=)
WO (1) WO2001021196A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210017504A (ko) * 2019-08-08 2021-02-17 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
EP3485921B1 (en) 2016-07-13 2025-07-23 Mochida Pharmaceutical Co., Ltd. Adhesion-preventing composition
WO2019138583A1 (ja) * 2018-01-15 2019-07-18 持田製薬株式会社 癒着防止用組成物
EP4126957A4 (en) * 2020-03-31 2024-07-24 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210017504A (ko) * 2019-08-08 2021-02-17 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물

Also Published As

Publication number Publication date
AU781442B2 (en) 2005-05-26
CA2384812A1 (en) 2001-03-29
AU7985000A (en) 2001-04-24
WO2001021196A1 (en) 2001-03-29
EP1223962A4 (en) 2004-01-21
EP1223962A1 (en) 2002-07-24
MXPA02003079A (es) 2004-04-21
BR0014222A (pt) 2003-02-25
CN1399554A (zh) 2003-02-26
JP2003509468A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
US20220313830A1 (en) Heparin-peptide bioconjugates and uses thereof
US7311911B2 (en) Methods for inhibiting angiogenesis
EP3185888B1 (en) Extracellular matrix compositions
CA2366880C (en) Compositions of polyacids and polyethers and methods for their use in reducing adhesions
EP2327451B1 (en) Method for detecting and inhibiting angiogenesis
JP2008163036A (ja) 治癒過程の調節
CN103732234A (zh) 使伤口愈合的装置和方法
US20170368192A1 (en) Luminal vessel coating for arteriovenous fistula
Back et al. Application of hyaluronic acid/sodium alginate-based microparticles to prevent tissue adhesion in a rabbit model
Hoban et al. Use of polypentapeptides of elastin to prevent postoperative adhesions: efficacy in a contaminated peritoneal model
KR20020048941A (ko) 유착 형성을 억제하기 위한 방법 및 조성물
CN102405050B (zh) 抑制细胞增殖和手术粘连的方法和组合物
Zhuang et al. A novel leptin receptor binding peptide tethered-collagen scaffold promotes lung injury repair
Kim et al. Efficacy and safety of hyaluronate membrane in the rabbit cecum-abdominal wall adhesion model
LT4192B (en) The use of fibrin-specific antibody as an antithrombic agent
Tran et al. An in vivo evaluation of a chondroitin sulfate solution to prevent postoperative intraperitoneal adhesion formation
CA3229366A1 (en) Fucan and modified fucan compositions for the treatment of conditions related to capsular contracture and to inhibiting fibrous growth around or on transplants
CN114452442A (zh) 一种原位诱导子宫壁组织再生的植入物
Hyacinthe et al. Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS)
Murthy et al. Inhibition of tumor implantation at sites of trauma by Arg-Gly-Asp containing proteins and peptides
Ettinger Bladder reconstruction with amniochorion
CN1286441C (zh) 医疗装置
Minteer Detection of Collagen in Rat Abdominal Wound Healing: Contributions of Mesenchymal Stromal Cells and Platelet-Rich Plasma
Khalil et al. Alexandria Journal of Veterinary Sciences

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050922

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060930

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20061228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060930

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I